Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

1,023.29 -4.38 (-0.43%)
Streaming Delayed Price Updated: 10:20 AM EDT, Jun 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,000 Today
Via Benzinga
Could This Biosimilar Drug Be Novartis' Next Blockbuster?
Novartis expects to submit regulatory applications for its biosimilar soon. 
Via The Motley Fool
Is REGENERON PHARMACEUTICALS (NASDAQ:REGN) suited for quality investing?
This article explores why quality investors may have a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN) 
Via Chartmill
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
Via Benzinga
Small Cancer Therapy Player Celularity To Provide Research Support For Regeneron's Therapy
Celularity Inc (NASDAQ: CELU) shares are trading higher after the company announced a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals Inc (NASDAQ: REGN). 
Via Benzinga
Wall Street Thinks This Tiny Biotech Company Could Soar Soon
An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle. 
Via The Motley Fool
Check Out What Whales Are Doing With REGN
Via Benzinga
Is Regeneron Stock a Buy Now?
The company's growth fuel isn't running out yet. 
Via The Motley Fool
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
These Are the ONLY 7 Penny Stocks to Consider in August 2023
These are just a few of the most promising penny stocks to consider as we head into the final months of the year. 
Via InvestorPlace
Could This Medicine Be the Next Winner for Novartis?
The Swiss drugmaker recently reported that a drug candidate met the primary endpoints in phase 3 clinical trials. 
Via The Motley Fool
Top 5 Health Care Stocks That May Fall Off A Cliff
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Regeneron Awarded $326M Government Contract For COVID-19 Antibody Therapy Development
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was awarded a government contract valued at up to $326 million on Tuesday. 
Via Benzinga
Exposures COVID-19
Regeneron's Crucial Eylea HD Approval: A Shield Against Potential Biosimilar Competition?
Friday, the FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration, diabetic macular edema,  
Via Benzinga
Exposures Product Safety
18 Analysts Have This to Say About Regeneron Pharmaceuticals
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $5,400 Today
Via Benzinga
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Via Benzinga
Value Stocks Outshine Growth Amidst Rising Treasury Yields: Key Sectors and Stocks Analyzed
The Vanguard Value Index Fund ETF (ARCA: VTV) has beaten the Vanguard Growth Index Fund ETF (ARCA: VUG) by 5% during the past month. The momentum shift comes as investors recalibrate their strategies... 
Via Benzinga
Topics ETFs
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years. 
Via Talk Markets
FDA Approves Regeneron's Drug For Ultra Rare Immune Disorder
The FDA approved  Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Veopoz (pozelimab-bbfg) for adult and pediatric patients one year of age and older with CHAPLE disease, known as CD55-deficient  
Via Benzinga
Exposures Product Safety
Why This Regeneron Approval 'Could Not Come Soon Enough' As Novartis Looms
The FDA signed off on Regeneron's high-dose Eylea about two months earlier than expected. 
Via Investor's Business Daily
Exposures Product Safety
Why the quality investor may take a look at NASDAQ:REGN.
REGENERON PHARMACEUTICALS (NASDAQ:REGN) may be suited for quality investing, we'll explore why in this article. 
Via Chartmill
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Via Benzinga
FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness
The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),  
Via Benzinga
Exposures Product Safety
Is Regeneron Pharmaceuticals Still a Top Growth Stock?
The biotech's focus on innovation could be a boon for shareholders. 
Via The Motley Fool
Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales
The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease. 
Via Investor's Business Daily
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be... 
Via Benzinga
The 7 Best Value Stocks to Buy in August
Stop chasing the hot flavors of the week and instead be friendly to your wallet with these ideas for best value stocks to buy. 
Via InvestorPlace
Regeneron's Aflibercept 8mg Shows Sustained Vision Gains At Two Years
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced two-year (96 weeks) topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related  
Via Benzinga
3 Top Biotech Stocks Defying the Bear Market
Biotech is still booming, if you pick the right biotech stocks. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.